IP Verse

Pharmaceutical Formulations Of A Hif Hydroxylase Inhibitor

Patent No. EP3003284 (titled "Pharmaceutical Formulations Of A Hif Hydroxylase Inhibitor") was filed by Fibrogen, Inc. on Jun 5, 2014. The application was issued on Feb 12, 2020.

Patent Summary

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
SANDOZNov 12, 2020TER MEER STEINMEISTER & PARTNER GBR
TEVA PHARMACEUTICAL INDUSTRIES LTDNov 11, 2020D YOUNG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP3003284

FIBROGEN, INC.
Application Number
EP14735770A
Filing Date
Jun 5, 2014
Status
Revoked
Apr 2, 2025
Publication Date
Feb 12, 2020
External Links
Slate, Register , Google Patents